Ceres Pharma
The computed 12-month bankruptcy probability of Ceres Pharma is 0.7% (low). The company has been active since 2015 and the Belgian State Gazette contains no insolvency or warning signals. No processed annual-account figures are available; this conclusion rests on registry and State Gazette data only.
| Active | 10 yrs |
| Board | 1 |
| Locations | 1 |
| Publications | 20 |
Statistical estimate based on public sources, not credit advice nor a finding of fact. How do we compute this?
| Fiscal year | Type | Filed | Reference |
|---|---|---|---|
| 31-12-2024 | volledig | 30-07-2025 | 2025-00344192 |
| 31-12-2023 | volledig | 25-07-2024 | 2024-00290448 |
| 31-12-2022 | volledig | 29-08-2023 | 2023-00405253 |
| 31-12-2022 | consolidatie | 02-10-2023 | 2023-00471130 |
| 31-12-2021 | volledig | 11-08-2022 | 2022-20288392 |
| 31-12-2020 | volledig | 16-07-2021 | 2021-36700460 |
| 31-12-2019 | volledig | 25-08-2020 | 2020-44700170 |
| 31-12-2018 | verkort | 30-08-2019 | 2019-59700049 |
| 31-12-2017 | verkort | 28-08-2018 | 2018-52200468 |
| 31-03-2017 | verkort | 05-10-2017 | 2017-66700344 |
-
Ceres InvestLegal entityDirector· perm. rep.: Mario Leo DEBELState Gazette act 21368778 (24-11-2021)Current28-10-2021 → present
Historic, not recently confirmed (5)
-
Not recently confirmedlast confirmed in an act from 2020
-
Juleste ConsultingLegal entityDirector· perm. rep.: Nathalie BaertState Gazette act 20092313 (11-08-2020)Not recently confirmedlast confirmed in an act from 2020
-
Not recently confirmedlast confirmed in an act from 2018
-
Not recently confirmedlast confirmed in an act from 2016
-
MD CONSULTLegal entityManaging director· perm. rep.: Mario DebelState Gazette act 15163584 (23-11-2015)Not recently confirmedlast confirmed in an act from 2015
Former directors (7)
-
AquitaniaLegal entityDirector· perm. rep.: Anja IMSCHOOTState Gazette act 21368778 (24-11-2021)Former- → 28-10-2021
-
Aubisque BVLegal entityDirector· perm. rep.: Freya LoncinState Gazette act 21146838 (16-12-2021)Former- → 28-10-2021
-
CRESCEMUS BVLegal entityDirector· perm. rep.: Pieter BourgeoisState Gazette act 21146838 (16-12-2021)Former- → 28-10-2021
-
Juleste Consulting BVLegal entityDirector· perm. rep.: Nathalie BaertState Gazette act 21146838 (16-12-2021)Former- → 28-10-2021
-
MD CONSULTLegal entityDirector· perm. rep.: Mario DEBELState Gazette act 21368778 (24-11-2021)Former- → 28-10-2021
-
Michael Schenck BVBALegal entityDirector· perm. rep.: Michael SchenckState Gazette act 18171544 (30-11-2018)Former- → 12-11-2018
-
Former12-11-2015 → 01-03-2016
2 events
- 01-03-2016 Resigned· Director
- 12-11-2015 Appointed· Director
| Statutory auditor | IRE/IBR number | Tenure |
|---|---|---|
| PricewaterhouseCoopers, BedrijfsrevisorenCurrent Company auditor · represented by Wouter Coppens |
- | 06-10-2022 → present |
| Pwc BedrijfsrevisorenCurrent Company auditor · represented by OPSOMER Peter |
- | 28-10-2021 → present |
| BV PwC Bedrijfsrevisoren Statutory auditor · represented by Wouter Coppens succeeded by PricewaterhouseCoopers, Bedrijfsrevisoren in 2022 |
- | 21-12-2020 → 06-10-2022 |
| NACE primary | Vervaardiging van andere voedingsmiddelen, neg(10890) |
| Legal form | Public limited company(014) |
| Incorporation | 28-10-2015 |
| Status | Active |
| Postal code | 9051 |
Each band states what its claims rest on. A board seat is influence over the board, not ownership. Court mandates (receiver, interim administrator) and liquidation mandates do not link companies and are therefore absent here; they belong under Directors & mandates.
Parcels linked to this company through its CBE addresses (seat, establishment units, branches), cross-referenced with the cadastral parcel plan. This shows where the company operates, not a deeds register.
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 44062B0301/00D003 | Flanders | 1.1 ha | 1 · 3,960 m² | - |
A single timeline of everything that happened to this company, publications, insolvency and lifecycle events, administrative changes and filed annual accounts.
28-11-2025 Capital increase of €50,375,234.71 to €50,375,234.71
Technical details
{
"events": [
{
"kind": "capital_increase",
"amount": 50375234.71,
"currency": "EUR",
"after_eur": 50375234.71,
"delta_eur": 50375234.71,
"before_eur": null,
"amount_type": "kapitaal_effectief",
"effective_date": "2024-05-13",
"evidence_quote": "De vergadering stelt vast en verzoekt ons, notaris, akte te nemen van het feit dat de voormelde kapitaalverhoging daadwerkelijk verwezenlijkt werd en dat het kapitaal aldus daadwerkelijk gebracht werd op EUR 50.375.234,71",
"contribution_type": "in_kind"
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0641.953.324",
"name_full": "CERES PHARMA",
"legal_form": "NV"
}
}19-08-2025 Wouter Coppens appointed as statutory auditor
- Wouter Coppens, Commissaris
Technical details
{
"events": [
{
"kind": "commissaris_in",
"role": "commissaris",
"person": {
"rrn": null,
"name": "Wouter Coppens",
"address": null,
"birth_date": null
},
"via_org": {
"kbo": null,
"name": "PwC Bedrijfsrevisoren BV",
"address": null,
"country": null,
"legal_form": null
},
"effective_date": "2023-07-01",
"evidence_quote": "De algemene vergadering benoemt PwC Bedrijfsrevisoren BV, met maatschappelijke zetel te 1831 Diegem, Culliganlaan 5, als commissaris voor een termijn van drie jaar."
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0641.953.324",
"name_full": "CERES PHARMA",
"legal_form": "NV"
}
}03-09-2024 Wouter Coppens reappointed as statutory auditor
- Wouter Coppens, Commissaris
Technical details
{
"events": [
{
"kind": "commissaris_renew",
"role": "commissaris",
"person": {
"rrn": null,
"name": "Wouter Coppens",
"address": null,
"birth_date": null
},
"via_org": {
"kbo": "0641953324",
"name": "PwC Bedrijfsrevisoren BV",
"address": null,
"country": null,
"legal_form": null
},
"effective_date": "2023-07-01",
"evidence_quote": "De firma PwC Bedrijfsrevisoren BV zal vanaf 1 juli 2023 vertegenwoordigd worden door de heer Wouter Coppens, in de uitoefening van zijn mandaat van commissaris, ter vervanging van de heer Peter Opsomer."
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0641.953.324",
"name_full": "CERES PHARMA",
"legal_form": "NV"
}
}27-05-2024 Capital increase of €4,608,796.87 to €50,375,234.71
- €45.766.437,84 → €50.375.234,71
Technical details
{
"events": [
{
"kind": "capital_increase",
"amount": 4608796.87,
"currency": "EUR",
"after_eur": 50375234.71,
"delta_eur": 4608796.87,
"before_eur": 45766437.84,
"amount_type": "kapitaal_effectief",
"effective_date": "2024-05-13",
"evidence_quote": "De vergadering beslist het kapitaal van de Vennootschap te verhogen ten belope van EUR 4.608.796,87, om het van EUR 45.766.437,84 te brengen op EUR 50.375.234,71, door uitgifte van 15.362.656 aandelen ... De vergadering beslist dat de kapitaalverhoging zal worden verwezenlijkt door de inbreng door de enige aandeelhouder van een zekere, vaststaande en opeisbare schuldvordering",
"contribution_type": "in_kind"
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0641.953.324",
"name_full": "CERES PHARMA",
"legal_form": "NV"
}
}31-01-2024 Capital increase of €9,999,999.90 to €45,766,437.84
- €35.766.437,94 → €45.766.437,84
Technical details
{
"events": [
{
"kind": "capital_increase",
"amount": 9999999.9,
"currency": "EUR",
"after_eur": 45766437.84,
"delta_eur": 9999999.9,
"before_eur": 35766437.94,
"amount_type": "kapitaal_effectief",
"effective_date": "2023-12-21",
"evidence_quote": "De vergadering beslist het kapitaal van de Vennootschap te verhogen ten belope van 9.999.999,90 EUR, om het van 35.766.437,94 EUR te brengen op 45.766.437,84 EUR, door inbreng in geld",
"contribution_type": "cash"
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0641.953.324",
"name_full": "CERES PHARMA",
"legal_form": "NV"
}
}17-05-2023 Capital increase of €3,499,997.94 to €35,766,437.94
- €32.266.440 → €35.766.437,94
Technical details
{
"events": [
{
"kind": "capital_increase",
"amount": 3499997.94,
"currency": "EUR",
"after_eur": 35766437.94,
"delta_eur": 3499997.94,
"before_eur": 32266440.0,
"amount_type": "kapitaal_effectief",
"effective_date": "2023-05-05",
"evidence_quote": "De vergadering beslist het kapitaal van de Vennootschap te verhogen ten belope van 3.499.997,94 EUR, om het van 32.266.440,00 EUR te brengen op 35.766.437,94 EUR, door inbreng in geld",
"contribution_type": "cash"
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0641.953.324",
"name_full": "CERES PHARMA",
"legal_form": "NV"
}
}18-10-2022 Capital increase of €4,356,000 to €28,473,000
- €24.117.000 → €28.473.000
- 2 kapitaalbewegingen in deze akte
Technical details
{
"events": [
{
"kind": "capital_increase",
"amount": 4356000,
"currency": "EUR",
"after_eur": 28473000,
"delta_eur": 4356000,
"before_eur": 24117000,
"amount_type": "kapitaal_effectief",
"effective_date": "2022-10-06",
"evidence_quote": "De vergadering beslist het kapitaal van de Vennootschap te verhogen ten belope van 4.356.000 EUR, om het van 24.117.000 EUR te brengen op 28.473.000 EUR, door inbreng in geld",
"contribution_type": "cash"
},
{
"kind": "capital_increase",
"amount": 3793440,
"currency": "EUR",
"after_eur": 32266440,
"delta_eur": 3793440,
"before_eur": 28473000,
"amount_type": "kapitaal_effectief",
"effective_date": "2022-10-06",
"evidence_quote": "De vergadering beslist het kapitaal van de Vennootschap te verhogen ten belope van 3.793.440 EUR om het van 28.473.000 EUR te brengen op 32.266.440 EUR, door inbreng in natura",
"contribution_type": "in_kind"
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0641.953.324",
"name_full": "CERES PHARMA",
"legal_form": "NV"
}
}15-02-2022 Registered office moved from Merelbeke to Sint-Denijs-Westrem
- Lembergsesteenweg 25, 9820 Merelbeke → Kortrijksesteenweg 1091, 9051 Sint-Denijs-Westrem
Technical details
{
"events": [
{
"kind": "zetel_transfer",
"seat_type": "statutaire",
"new_address": {
"city": "Sint-Denijs-Westrem",
"region": null,
"street": "Kortrijksesteenweg",
"country": "BE",
"postcode": "9051",
"box_number": "B",
"street_number": "1091"
},
"old_address": {
"city": "Merelbeke",
"region": null,
"street": "Lembergsesteenweg",
"country": "BE",
"postcode": "9820",
"box_number": "A",
"street_number": "25"
},
"effective_date": "2022-01-25",
"evidence_quote": "De bestuurder besluit om de zetel te verplaatsen van Lembergsesteenweg 25a, 9820 Merelbeke, naar Kortrijksesteenweg 1091 bus B, 9051 Sint-Denijs-Westrem, met ingang van heden."
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0641.953.324",
"name_full": "CERES PHARMA",
"legal_form": "NV"
}
}16-12-2021 3 resigning
- Pieter Bourgeois, Bestuurder
- Nathalie Baert, Bestuurder
- Freya Loncin, Bestuurder
Technical details
{
"events": [
{
"kind": "director_out",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Pieter Bourgeois",
"address": null,
"birth_date": null
},
"via_org": {
"kbo": null,
"name": "CRESCEMUS BV",
"address": null,
"country": null,
"legal_form": null
},
"effective_date": "2021-10-28",
"evidence_quote": "De enige aandeelhouder neemt kennis van het ontslag van de volgende personen als bestuurders van de Vennootschap, met onmiddellijke ingang vanaf 28 oktober 2021: - CRESCEMUS BV, vast vertegenwoordigd door Pieter Bourgeois;"
},
{
"kind": "director_out",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Nathalie Baert",
"address": null,
"birth_date": null
},
"via_org": {
"kbo": null,
"name": "Juleste Consulting BV",
"address": null,
"country": null,
"legal_form": null
},
"effective_date": "2021-10-28",
"evidence_quote": "De enige aandeelhouder neemt kennis van het ontslag van de volgende personen als bestuurders van de Vennootschap, met onmiddellijke ingang vanaf 28 oktober 2021: - Juleste Consulting BV, vast vertegenwoordigd door Nathalie Baert;"
},
{
"kind": "director_out",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Freya Loncin",
"address": null,
"birth_date": null
},
"via_org": {
"kbo": null,
"name": "AUBISQUE BV",
"address": null,
"country": null,
"legal_form": null
},
"effective_date": "2021-10-28",
"evidence_quote": "De enige aandeelhouder neemt kennis van het ontslag van de volgende personen als bestuurders van de Vennootschap, met onmiddellijke ingang vanaf 28 oktober 2021: - AUBISQUE BV, vast vertegenwoordigd door Freya Loncin."
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0641.953.324",
"name_full": "CERES PHARMA",
"legal_form": "NV"
}
}24-11-2021 1 director appointed, 5 resigning
- Mario Leo DEBEL, Bestuurder
- Nathalie BAERT, Bestuurder
- Freya LONCIN, Bestuurder
- Pieter BOURGEOIS, Bestuurder
- Anja IMSCHOOT, Bestuurder
- Mario DEBEL, Bestuurder
Technical details
{
"events": [
{
"kind": "director_out",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Nathalie BAERT",
"address": null,
"birth_date": null
},
"via_org": {
"kbo": null,
"name": "Juleste Consulting BV",
"address": null,
"country": null,
"legal_form": null
},
"effective_date": "2021-10-28",
"evidence_quote": "De vergadering neemt kennis van en bevestigt het ontslag van de volgende bestuurders met ingang vanaf 28 oktober 2021, waartoe werd besloten krachtens een onderhandse beslissing van de bijzondere algemene vergadering de dato 28 oktober 2021: - de besloten vennootschap \u0022Juleste Consulting BV\u0022 met als"
},
{
"kind": "director_out",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Freya LONCIN",
"address": null,
"birth_date": null
},
"via_org": {
"kbo": null,
"name": "Aubisque BV",
"address": null,
"country": null,
"legal_form": null
},
"effective_date": "2021-10-28",
"evidence_quote": "De vergadering neemt kennis van en bevestigt het ontslag van de volgende bestuurders met ingang vanaf 28 oktober 2021, waartoe werd besloten krachtens een onderhandse beslissing van de bijzondere algemene vergadering de dato 28 oktober 2021: - de besloten vennootschap \u0022Aubisque BV\u0022 met als vaste ver"
},
{
"kind": "director_out",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Pieter BOURGEOIS",
"address": null,
"birth_date": null
},
"via_org": {
"kbo": null,
"name": "Crescemus BV",
"address": null,
"country": null,
"legal_form": null
},
"effective_date": "2021-10-28",
"evidence_quote": "De vergadering neemt kennis van en bevestigt het ontslag van de volgende bestuurders met ingang vanaf 28 oktober 2021, waartoe werd besloten krachtens een onderhandse beslissing van de bijzondere algemene vergadering de dato 28 oktober 2021: - de besloten vennootschap \u0022Crescemus BV\u0022 met als vaste ve"
},
{
"kind": "director_out",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Anja IMSCHOOT",
"address": null,
"birth_date": null
},
"via_org": {
"kbo": null,
"name": "Aquitania",
"address": null,
"country": null,
"legal_form": null
},
"effective_date": "2021-10-28",
"evidence_quote": "De vergadering neemt kennis van en aanvaardt het ontslag van de volgende bestuurders met ingang vanaf achtentwintig oktober tweeduizend eenentwintig: - - de besloten vennootschap \u0022Aquitania\u0022 met als vaste vertegenwoordiger mevrouw Anja IMSCHOOT; en - - de besloten vennootschap \u0022MD CONSULT\u0022 met als v",
"discharge_granted": true
},
{
"kind": "director_out",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Mario DEBEL",
"address": null,
"birth_date": null
},
"via_org": {
"kbo": null,
"name": "MD CONSULT",
"address": null,
"country": null,
"legal_form": null
},
"effective_date": "2021-10-28",
"evidence_quote": "De vergadering neemt kennis van en aanvaardt het ontslag van de volgende bestuurders met ingang vanaf achtentwintig oktober tweeduizend eenentwintig: - - de besloten vennootschap \u0022Aquitania\u0022 met als vaste vertegenwoordiger mevrouw Anja IMSCHOOT; en - - de besloten vennootschap \u0022MD CONSULT\u0022 met als v",
"discharge_granted": true
},
{
"kind": "director_in",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Mario Leo DEBEL",
"address": null,
"birth_date": null
},
"via_org": {
"kbo": null,
"name": "Ceres Invest",
"address": null,
"country": null,
"legal_form": null
},
"effective_date": "2021-10-28",
"evidence_quote": "De vergadering beslist te benoemen als niet-statutaire bestuurder van de Vennootschap, vanaf achtentwintig oktober tweeduizend eenentwintig en dit voor een duur van 6 jaar: - de besloten vennootschap \u0022Ceres Invest\u0022, met als vaste vertegenwoordiger de heer DEBEL Mario Leo, wonende te 8300 Knokke-Heis"
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0641.953.324",
"name_full": "CERES PHARMA",
"legal_form": "NV"
}
}21-12-2020 Peter Opsomer appointed as statutory auditor
- Peter Opsomer, Commissaris
Technical details
{
"events": [
{
"kind": "commissaris_in",
"role": "commissaris",
"person": {
"rrn": null,
"name": "Peter Opsomer",
"address": null,
"birth_date": null
},
"via_org": {
"kbo": null,
"name": "BV PwC Bedrijfsrevisoren",
"address": null,
"country": null,
"legal_form": null
},
"evidence_quote": "De algemene vergadering benoemt de BV PwC Bedrijfsrevisoren, met maatschappelijke zetel te 1932 Sint-Stevens-Woluwe, Woluwedal 18, als commissaris voor een termijn van drie jaar. Deze vennootschap heeft de heer Peter Opsomer, bedrijfsrevisor, aangeduid als vertegenwoordiger die gemachtigd is haar te"
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0641.953.324",
"name_full": "CERES PHARMA",
"legal_form": "NV"
}
}11-08-2020 2 directors appointed
- Pieter Bourgeois, Bestuurder
- Nathalie Baert, Bestuurder
Technical details
{
"events": [
{
"kind": "director_in",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Pieter Bourgeois",
"address": null,
"birth_date": null
},
"via_org": {
"kbo": "0521873163",
"name": "Crescemus BV",
"address": null,
"country": null,
"legal_form": null
},
"effective_date": "2020-07-01",
"evidence_quote": "De algemene vergadering benoemt, met unanimiteit van stemmen (i) Crescemus BV, met zetel te Dr. Adriaan Martenslaan 6, 9800 Deinze, RPR Gent 0521.873.163, met vaste vertegenwoordiger Pieter Bourgeois, wonende te Dr. Adriaan Martenslaan 6, 9800 Deinze en (ii) Juleste Consulting BV, met zetel te Acaci"
},
{
"kind": "director_in",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Nathalie Baert",
"address": null,
"birth_date": null
},
"via_org": {
"kbo": "0668636737",
"name": "Juleste Consulting BV",
"address": null,
"country": null,
"legal_form": null
},
"effective_date": "2020-07-01",
"evidence_quote": "De algemene vergadering benoemt, met unanimiteit van stemmen (i) Crescemus BV, met zetel te Dr. Adriaan Martenslaan 6, 9800 Deinze, RPR Gent 0521.873.163, met vaste vertegenwoordiger Pieter Bourgeois, wonende te Dr. Adriaan Martenslaan 6, 9800 Deinze en (ii) Juleste Consulting BV, met zetel te Acaci"
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0641.953.324",
"name_full": "CERES PHARMA",
"legal_form": "NV"
}
}27-12-2018 Articles of association amended
Technical details
{
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"statute_change": {
"name_change": false,
"seat_change": false,
"object_change": false,
"effective_date": "2018-12-14",
"legal_form_change": false
},
"bedrijfsrevisor": null,
"subject_company": {
"kbo": "0641.953.324",
"name_full": "CERES PHARMA",
"legal_form": "NV"
},
"signature_regime": null,
"special_mandates": [],
"governance_change": {
"admin_delegated_added": []
}
}30-11-2018 1 director appointed, 1 resigning
- Anja Imschoot, Bestuurder
- Michael Schenck, Bestuurder
Technical details
{
"events": [
{
"kind": "director_out",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Michael Schenck",
"address": null,
"birth_date": null
},
"via_org": {
"kbo": null,
"name": "Michael Schenck BVBA",
"address": null,
"country": null,
"legal_form": null
},
"effective_date": "2018-11-12",
"evidence_quote": "De algemene vergadering neemt kennis van het ontslag van Michael Schenck BVBA, met zetel te 2018 Antwerpen, Maria-Henriettalei 10, bus 8, vertegenwoordigd door haar vaste vertegenwoordiger de heer Michael Schenck, wonende te 2018 Antwerpen, Maria-Henriettalel 10, bus 8, als bestuurder van de Vennoot"
},
{
"kind": "director_in",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Anja Imschoot",
"address": null,
"birth_date": null
},
"via_org": {
"kbo": "0666678822",
"name": "Aquitania BVBA",
"address": null,
"country": null,
"legal_form": null
},
"effective_date": "2018-11-12",
"evidence_quote": "De algemene vergadering benoemt, met unanimiteit van stemmen Aquitania BVBA, met zetel te 9070 Destelbergen, Reukenwegel 5A, RPR Gent, 0666.678.822, met vaste vertegenwoordiger Anja Imschoot, wonende te 9070 Destelbergen, Reukenwegel 5A, tot bestuurder van de Vennootschap, met ingang van heden."
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0641.953.324",
"name_full": "CERES PHARMA",
"legal_form": "NV"
}
}19-09-2018 Capital increase of €3,000,000 to €6,000,000
- €3.000.000 → €6.000.000
Technical details
{
"events": [
{
"kind": "capital_increase",
"amount": 3000000.0,
"currency": "EUR",
"after_eur": 6000000.0,
"delta_eur": 3000000.0,
"before_eur": 3000000.0,
"amount_type": "kapitaal_effectief",
"effective_date": "2018-09-06",
"evidence_quote": "het kapitaal van de vennootschap te verhogen met drie miljoen euro (\u20AC 3.000.000,00), teneinde het te brengen van drie miljoen euro (\u20AC 3.000.000,00) op zes miljoen euro (\u20AC 6.000.000,00), door inbreng in geld",
"contribution_type": "cash"
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0641.953.324",
"name_full": "CERES PHARMA",
"legal_form": "NV"
}
}29-01-2018 Capital increase of €1,500,000 to €3,000,000
- €1.500.000 → €3.000.000
Technical details
{
"events": [
{
"kind": "capital_increase",
"amount": 1500000.0,
"currency": "EUR",
"after_eur": 3000000.0,
"delta_eur": 1500000.0,
"before_eur": 1500000.0,
"amount_type": "kapitaal_effectief",
"effective_date": "2017-12-29",
"evidence_quote": "het kapitaal van de vennootschap te verhogen met \u00E9\u00E9n miljoen vijfhonderdduizend euro (\u20AC 1.500.000,00), teneinde het te brengen van \u00E9\u00E9n miljoen vijfhonderdduizend euro (\u20AC 1.500.000,00) op drie miljoen euro (\u042D 3.000.000,00)",
"contribution_type": "cash"
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0641.953.324",
"name_full": "CERES PHARMA",
"legal_form": "NV"
}
}06-10-2017 Articles of association amended
Technical details
{
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"statute_change": {
"name_change": true,
"seat_change": false,
"object_change": false,
"effective_date": "2017-09-15",
"legal_form_change": false
},
"bedrijfsrevisor": null,
"subject_company": {
"kbo": "0641.953.324",
"name_full": "PHARCO INNOVATIONS",
"legal_form": "NV"
},
"signature_regime": null,
"special_mandates": [
{
"quote": "bijzondere volmacht, met recht van in de plaatsstelling, te verlenen aan mevrouw Nathalie BAERT om alle administratieve formaliteiten te vervullen in verband met deze wijziging van de statuten en in het bijzonder de formaliteiten bij \u00E9\u00E9n of meer erkende ondernemingsloketten en/of bij de btw-administratie.",
"holder_kbo": null,
"holder_name": "Nathalie BAERT",
"scope_categories": [
"administrative_formalities",
"KBO",
"tax",
"filing"
],
"with_substitution": true
}
],
"governance_change": {
"admin_delegated_added": []
}
}17-03-2016 1 director appointed, 1 resigning
- Freya Loncin, Bestuurder
- Freya Loncin, Bestuurder
Technical details
{
"events": [
{
"kind": "director_out",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Freya Loncin",
"address": null,
"birth_date": null
},
"via_org": {
"kbo": "0895140645",
"name": "Alychlo NV",
"address": null,
"country": null,
"legal_form": null
},
"effective_date": "2016-03-01",
"evidence_quote": "De algemene vergadering neemt kennis van het ontslag van Alychlo NV, met zetel te Lembergsesteenweg 19, 9820 Merelbeke, met ondernemingsnummer 0895.140.645, met vaste vertegenwoordiger Freya Loncin, wonende te Vlaamsekunstlaan 38, 2020 Antwerpen als bestuurder van de Vennootschap met ingang van hede"
},
{
"kind": "director_in",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Freya Loncin",
"address": null,
"birth_date": null
},
"via_org": {
"kbo": "0843087970",
"name": "Aubisque BVBA",
"address": null,
"country": null,
"legal_form": null
},
"effective_date": "2016-03-01",
"evidence_quote": "De algemene vergadering benoemt met ingang van heden, Aubisque BVBA, met zetel te Vlaamsekunstlaan 38, 2020 Antwerpen, met ondememingsnummer 0843.087.970, met vaste vertegenwoordiger Freya Loncin, wonende te Vlaamsekunstlaan 38, 2020 Antwerpen, als bestuurder van de Vennootschap."
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0641.953.324",
"name_full": "PHARCO INNOVATIONS",
"legal_form": "NV"
}
}23-11-2015 2 directors appointed
- Mario Debel, Gedelegeerd bestuurder
- Freya Loncin, Bestuurder
Technical details
{
"events": [
{
"kind": "director_in",
"role": "gedelegeerd_bestuurder",
"person": {
"rrn": null,
"name": "Mario Debel",
"address": null,
"birth_date": null
},
"via_org": {
"kbo": "0471608456",
"name": "bvba MD Consult",
"address": null,
"country": null,
"legal_form": null
},
"effective_date": "2015-11-12",
"evidence_quote": "Aansluitend komt de Raad van Bestuur bijeen om te benoemen: - bvba MD Consult 0471.608.456, Hillestraat 12 te 8800 Roeselare met als vast vertegenwoordiger de heer Mario Debel, als gedelegeerd bestuurder"
},
{
"kind": "director_in",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Freya Loncin",
"address": null,
"birth_date": null
},
"via_org": {
"kbo": "0895140645",
"name": "nv Alychlo",
"address": null,
"country": null,
"legal_form": null
},
"effective_date": "2015-11-12",
"evidence_quote": "Aansluitend komt de Raad van Bestuur bijeen om te benoemen: - nv Alychlo 0895.140.645, Lembergsesteenweg 19, 9820 Merelbeke, met vast vertegenwoordiger mevrouw Freya Loncin, als voorzitter Raad van Bestuur"
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0641.953.324",
"name_full": "PHARCO INNOVATIONS",
"legal_form": "NV"
}
}30-10-2015 Incorporation of a new NV
Technical details
{
"kind": "oprichting",
"seat": "9820 Merelbeke, Lembergsesteenweg 19",
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"founders": [
{
"org": {
"kbo": "0895.140.645",
"name": "ALYCHLO"
},
"kind": "rechtspersoon",
"person": null,
"share_class": "Ordinary",
"partner_role": null,
"holder_org_kbo": "0895.140.645",
"holder_org_name": "ALYCHLO",
"contribution_type": "cash",
"amount_paid_in_eur": 1200000,
"holder_person_name": null,
"is_subscriber_only": false,
"n_shares_subscribed": 1200,
"amount_subscribed_eur": 1200000,
"is_anonymous_silent_partner": false
},
{
"org": null,
"kind": "natural_person",
"person": {
"dob": "1970-04-04",
"name": "Mario Leo DEBEL",
"niss": null,
"address": "8800 Roeselare, Hillestraat 12"
},
"share_class": "Ordinary",
"partner_role": null,
"holder_org_kbo": null,
"holder_org_name": null,
"contribution_type": "cash",
"amount_paid_in_eur": 300000,
"holder_person_name": "Mario Leo DEBEL",
"is_subscriber_only": false,
"n_shares_subscribed": 300,
"amount_subscribed_eur": 300000,
"is_anonymous_silent_partner": false
}
],
"capital_eur": 1500000,
"subject_company": {
"kbo": "0641.953.324",
"name_full": "Pharco Innovations",
"legal_form": "NV"
},
"initial_directors": [],
"incorporation_date": "2015-10-27",
"post_incorporation_mandates": []
}Generate a structured, factual brief from every signal in this dossier: risk, financial health, ownership, mandates and sector comparison.
| Legal nameNL | Ceres Pharma |